The short answer
Viennois and colleagues reported in 2016 that KPV's effect in a mouse model vanished in animals whose PepT1 transporter had been deleted. A genetic control of that kind tests a proposed mechanism directly, in a way that concentration-response data cannot.
Key facts
- Publication
- Cell Mol Gastroenterol Hepatol 2016 (PMID 27458604)
- Animals used
- Wild-type, hPepT1-overexpressing transgenic, PepT1 knockout mice
- Model
- AOM/DSS in mice
- Transgenic result
- Larger tumours, greater burden, more inflammation than wild type
- Knockout result
- Fewer and smaller tumours, less inflammation
- KPV in wild-type mice
- Reduced tumorigenesis in the model
- KPV in knockout mice
- No inhibitory effect observed
- Human tissue finding
- Increased PepT1 expression in colorectal tumour biopsies
What a knockout control is for
A concentration-response curve tells you that more of a compound produces more of an effect. It does not tell you which molecular route the compound took to produce it. Competition and labelled uptake experiments narrow the possibilities but still leave room for a compound to be transported by one route and to act through another. The decisive experiment is to remove the proposed route entirely and see whether the effect survives. If it does, the route was not necessary. If it does not, the route was load-bearing.
What was done
Three genotypes were used: wild-type mice, mice overexpressing human PepT1 in intestinal epithelial cells, and mice with PepT1 deleted. Colitis-associated tumorigenesis was induced with azoxymethane and dextran sulfate sodium. The transporter's own contribution was measured first: transgenic mice had larger tumours, greater tumour burden and more intestinal inflammation than wild-type; knockout mice had significantly fewer and smaller tumours and less inflammation. Proliferating crypt cells followed the same pattern in both directions. Human colonic biopsies showed increased PepT1 expression in patients with colorectal cancer.
Research material referenced
KPV 10mg, third-party HPLC tested
The result that matters for KPV
KPV was then given to wild-type mice, where the authors report it prevented carcinogenesis in the model. The same compound given to PepT1 knockout mice produced none of the inhibitory effect seen in wild-type animals. The compound is unchanged; the animal's transporter is not there; the effect is gone. That is about as direct a test of a delivery mechanism as an animal experiment provides, and it converts 'KPV is a PepT1 substrate and also does something' into 'KPV does that thing by way of PepT1'.
Reading the two halves of this paper correctly
The paper contains two findings that pull in opposite directions and are easy to conflate. The transporter itself was associated with worse outcomes in this model: more PepT1 meant more tumour, less PepT1 meant less. A tripeptide that requires that same transporter to act was associated with better outcomes in animals that had it. Those are not contradictory (the transporter's own role and the effect of one of its substrates are separate questions), but any summary that reports one without the other misrepresents the paper. The authors' own conclusion is about PepT1 as a potential target, not about KPV as a treatment.
What an animal model of this kind is and is not
Azoxymethane with dextran sulfate sodium is a chemically induced model of inflammation-associated tumorigenesis in mice. It is a standard laboratory tool for studying the link between chronic inflammation and tumour development, and it is not a model of any human disease in the sense of reproducing its cause, its course or its treatment. Results in it have repeatedly failed to translate. Reporting what a paper found in that model is a statement about the model.
The line this article does not cross
Nothing here says or implies that KPV treats, prevents or improves any condition in humans, and nothing here is a reason for anyone to take it. There are no human trials of KPV. It is supplied for laboratory research only. The reason to write about a knockout experiment is that it is unusually good evidence about a mechanism, and mechanism is what a reference library is for.
Frequently asked questions
Why is a knockout better evidence than a dose-response?
Because it tests necessity rather than association. A dose-response shows the compound and the effect move together; a knockout shows whether the proposed route is required for the effect to happen at all. The two answer different questions and the second is harder to explain away.
Could KPV act through some other route as well?
Possibly, and the knockout does not rule it out for effects the model did not measure. What it establishes is that for this outcome in this model, PepT1 was necessary. Other outcomes could in principle have other mechanisms.
Does more PepT1 mean worse disease?
In this particular model, yes. Overexpression increased tumour burden and inflammation and deletion decreased them, and human colorectal tumour biopsies showed increased expression. That is a finding about the transporter in this model and in that tissue sample, not a general rule about the transporter's role in health.
Has any of this been tested in people?
No trial of KPV in humans has been registered or reported. The human data in this paper is expression in biopsy tissue, not treatment of anyone with anything.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedViennois E et al., Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV - Cell Mol Gastroenterol Hepatol 2016 (PMID 27458604)pubmed.ncbi.nlm.nih.gov
- PubMedDalmasso G et al., PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation - Gastroenterology 2008 (PMID 18061177)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More KPV articles
- When the Tripeptide Is the Address, Not the CargoRecent work increasingly attaches KPV to something else - a dye, a nanoparticle, a drug carrier - and uses its affinity to reach cells overexpressing PepT1.
- A Second Claim, With a Different MechanismWork from 2000 reported that alpha-MSH and its KPV fragment inhibited Staphylococcus aureus and Candida albicans. That is not the anti-inflammatory claim.
- The Part of the Hormone That Talks to the Receptor Is Not in KPVMelanocortin receptor activation requires the His-Phe-Arg-Trp core, and that tetrapeptide alone is an agonist. KPV is residues 11 to 13 and contains none of it.
- Nanomolar in a Dish Is Not a DoseAlmost every quantitative claim about KPV traces back to immortalised cell lines and mouse models. Here is precisely what each of those can and cannot support.
- What Is KPV? The Tripeptide From Alpha-MSHKPV is Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH, at 342.43 Da. It carries reported anti-inflammatory activity without the pigmentation effects.